Investing

BioAtla : BCAB

BCAB

Stock Data

$4.27

$0.06 (1.43%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

BioAtla Inc is a pioneering biopharmaceutical company focused on developing targeted therapies for solid tumor cancers. With a strong emphasis on antibody-based treatments, its flagship product, BA3011, is designed to combat various cancers including lung, ovarian, and sarcomas. Additionally, BioAtla is advancing BA3021 and BA3071, aimed at addressing a broad range of solid tumors and specific cancers such as melanoma and renal cell carcinoma. Founded in 2007, this San Diego-based company is at the forefront of creating conditionally active biologics to improve cancer treatment outcomes.

All BioAtla Articles

1 Article

Gerelyn Terzo | Jul 9, 2024 at 10:47 AM EDT

3 Penny Stocks With 735% Average Upside, According to Wall Street

With the third quarter in full swing, the bulls have not lost their grip on equities. The market momentum isn’t…